Biohaven Pharmaceutical is a clinical-stage biopharmaceutical company with a portfolio of late-stage product candidates targeting central nervous system diseases. Co.'s product candidates are small molecules and based on three mechanistic platforms-calcitonin gene-related peptide (CGRP) receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Co. is developing rimegepant as an orally available, selective and small molecule CGRP receptor antagonist for the acute and preventive treatment of migraine. Co. is developing troriluzole and BHV-0223, acting as glutamate transporter modulators, while BHV-5000 is an antagonist of the glutamate N-methyl-D-aspartate receptor. The BHVN stock yearly return is shown above.
The yearly return on the BHVN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BHVN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|